| BCRJ Code | 0006 |
| Cell Line | 1F5 |
| Species | Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma) |
| Vulgar Name | Mouse |
| Cell Type | Hybridoma: B Lymphocyte |
| Morphology | Lymphoblast |
| Growth Properties | Suspension |
| Products | Immunoglobulin; monoclonal antibody; against human CD20 B cell antigen (Bp35) |
| Biosafety | 1 |
| Addtional Info | The antibody is specific for CD20 (expressed on normal and neoplastic human B cells) and can induce proliferation of resting B cells. |
| Culture Medium | RPMI-1640 medium modified to contain 2 mM L-glutamine, 1 mM sodium pyruvate, 4500 mg/L glucose and fetal bovine serum to a final concentration of 10%. |
| Subculturing | Cultures can be maintained by addition of fresh medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 x 10e5 viable cells/mL. Maintain cultures at a cell concentration between 1 x 10e5 and 1 x 10e6 cells/mL. NOTE: Do not allow the cell concentration to exceed 1 x 10e6 cells/mL. |
| Subculturing Medium Renewal | Every 2 to 3 days |
| Culture Conditions | Atmosphere: air, 95%; carbon dioxide (CO2), 5% Temperature: 37°C |
| Cryopreservation | 95% FBS + 5% DMSO (Dimethyl sulfoxide) |
| Thawing Frozen Cells | SAFETY PRECAUTION:
It is strongly recommended to always wear protective gloves, clothing, and a full-face mask when handling frozen vials. Some vials may leak when submerged in liquid nitrogen, allowing nitrogen to slowly enter the vial. Upon thawing, the conversion of liquid nitrogen back to its gas phase may cause the vial to explode or eject its cap with significant force, creating flying debris.
NOTE: It is important to avoid excessive alkalinity of the medium during cell recovery. To minimize this risk, it is recommended to place the culture vessel containing the growth medium in the incubator for at least 15 minutes before adding the vial contents. This allows the medium to stabilize at its normal pH (7.0 to 7.6). |
| References | Senter PD, et al. Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells. US Patent 4,975,278 dated Dec 4 1990. Clark EA, et al. Role of the Bp35 cell surface polypeptide in human B-cell activation. Proc. Natl. Acad. Sci. USA 82: 1766-1770, 1985. PubMed: 3872456 |
| Depositors | Márcio Poças; Universidade de Brasília. |
| Cellosaurus | CVCL_D142 |
